Table 1 Patients’ socio-demographic and clinical characteristics at baseline
Characteristics | RON (n = 131) | PALOMA-2 (n = 444) | |
|---|---|---|---|
Simplified staging (TNM) at diagnosis, n (%) | I–III | 80 (61.1) | 260 (58.5) |
IV | 51 (38.9) | 138 (31.1) | |
Unknown/missing | 0 (0.0) | 46 (10.4) | |
Histologic subtype, n (%) | No special type invasive carcinoma | 109 (83.2) | NA |
Invasive lobular carcinoma tumor | 13 (9.9) | NA | |
Other | 9 (6.9) | NA | |
Age at initiation of treatment | Median (IQR 25–75) | 58 (47–67) | 62 (NA) |
Min–max | 27–80 | 30–89 | |
Disease extension and location of metastasis upon initiation of treatment, n (%) | M0 | 2 (1.5) | 0 (0.0) |
M1 | 129 | 444 (100.0) | |
Visceral | (98.5) | 214 (48.2) | |
Non visceral | 72 (55.8) | 230 (51.8) | |
Bone-only | 19 (14.7) | 103 (23.2)$ | |
38 (29.5) | |||
Performance status at treatment initiation, n (%) | 0–1 | 108 (94.7) | 435 (98.0) |
Unknown: n = 17 | ≥ 2 | 6 (5.3) | 9 (2.0) |
Menopausal status | Pre or peri menopausal | 43 (32.8) | 0 (0.0) |
Post-menopausal | 88 (67.2) | 444 (100.0) | |
Hormonal receptors status, n (%)* | Positive estrogen and/or progestogen receptors | 129 (100.0) | 444 (100.0) |
Not evaluated/unknown n = 2 | Negative estrogen and progestogen receptors | 0 (0.0) | 0 (0.0) |
HER2 Status, n (%)# | Positive | 0 (0.0) | 0 (0.0) |
Not evaluated/unknown n = 6 | Negative | 125 (100.0) | 444 (100.0) |